fda compounding semaglutide enforcement november 2025 September 15, 2025: Telehealth company must stop implying its compounded GLP-1 is FDA-approved, warns – Partnership for Safe Medicines The FDA has announced that

Semaglutide and heart failure: updated meta-analysis

Edvardsson CE, Adermark L, Gottlieb S, Alfreji S, Emous TA, Gouda Y, Thorsell A, Vujii M, Arans C, Benrick A, Wernstedt Asterholm I, Lopez MF, Becker HC, Jerlhag E

The majority of GLP-1 medications are only approved for adults 18 years and older

At the 12 mg dose at 48 weeks: -24.2% mean body weight versus -2.1% placebo

Multi-indication label expansion: Semaglutide approved across obesity, cardiovascular risk reduction, MASH, and sleep apnea creates a total addressable patient population of approximately 640 million globally nearly four times the obesity-only base adding new prescriber populations including cardiologists, hepatologists, and sleep medicine specialists